A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet.
Phase of Trial: Phase I
Latest Information Update: 10 May 2011
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease; Food hypersensitivity
- Focus Adverse reactions
- 09 May 2011 Results presented at the Digestive Disease Week in May 2011, according to an ImmusanT media release.
- 16 Mar 2011 New trial record
- 15 Mar 2011 Results will be presented at DDW-2011 according to an ImmusanT media release.